First preclinical data on DF-6215, an alpha-active superagonistic IL-2

Nov. 11, 2024

At the Society for Immunotherapy of Cancer (SITC) meeting that ended yesterday in Houston, Dragonfly Therapeutics Inc. reported the first preclinical data on DF-6215, an alpha-active IL-2-Fc, for cancer immunotherapy.

BioWorld Science Conferences Society for Immunotherapy of Cancer Cancer Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for April 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 22, 2025.

Makary’s vision for slimmed-down US FDA somewhat reassuring

BioWorld

Nearly three weeks into the job, U.S. FDA Commissioner Marty Makary provided a comprehensive overview of his vision for the much-reduced agency, even as he’s...

Dupixent bounces back in treating hives with FDA approval

BioWorld

The U.S. FDA issued a complete response letter in October 2023 for Dupixent (dupilumab) in treating chronic hives but has now approved the monoclonal antibody for...

Medtronic Simplera Sync and Minimed 780G pump system

Medtronic continues to close gap in diabetes tech

BioWorld MedTech

Medtronic plc’s diabetes unit posted another win with the U.S. FDA approval of the Simplera continuous glucose monitoring sensor for use with the Minimed 780G...